血清可溶性凝集素样氧化低密度脂蛋白受体-1水平与阻塞性睡眠呼吸暂停的存在及严重程度相关。
Serum sLOX-1 Levels Are Correlated with the Presence and Severity of Obstructive Sleep Apnea.
作者信息
Xu Chun-Yan, Li Da-Ju, Wu Chun-Ling, Lou Han-Jian, Jiang Hong-Wei, Ding Guo-Qiang
机构信息
1 Department of Stomatology, Yiwu Central Hospital , Yiwu, People's Republic of China .
出版信息
Genet Test Mol Biomarkers. 2015 May;19(5):272-6. doi: 10.1089/gtmb.2015.0027. Epub 2015 Mar 31.
CONTEXT
Inflammation plays a critical role in the development and progression of obstructive sleep apnea (OSA). Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) activation is involved in the pathophysiology of inflammatory process-related disorders.
OBJECTIVE
This study aims to investigate whether serum soluble LOX-1 (sLOX-1) levels are associated with the presence and severity of OSA.
MATERIALS AND METHODS
A total of 137 OSA patients and 78 controls were recruited in this study. Serum sLOX-1 levels were measured by enzyme-linked immunosorbent assay. The severity of OSA was assessed by the apnea-hypopnea index (AHI).
RESULTS
OSA patients had significantly higher serum sLOX-1 levels compared with controls. Serum sLOX-1 levels elevated with the increment of OSA severity. sLOX-1 was the independent predictor of OSA. Serum sLOX-1 levels were significantly correlated with AHI and high-sensitivity C-reactive protein levels.
CONCLUSIONS
Serum sLOX-1 levels were independently correlated with the presence and severity of OSA. These findings revealed that sLOX-1 might function as a potential biomarker for monitoring the development and progression of OSA.
背景
炎症在阻塞性睡眠呼吸暂停（OSA）的发生和发展中起关键作用。凝集素样氧化低密度脂蛋白受体-1（LOX-1）的激活参与炎症相关疾病的病理生理过程。
目的
本研究旨在探讨血清可溶性LOX-1（sLOX-1）水平是否与OSA的存在及严重程度相关。
材料与方法
本研究共纳入137例OSA患者和78例对照。采用酶联免疫吸附测定法检测血清sLOX-1水平。通过呼吸暂停低通气指数（AHI）评估OSA的严重程度。
结果
与对照组相比，OSA患者血清sLOX-1水平显著升高。血清sLOX-1水平随OSA严重程度的增加而升高。sLOX-1是OSA的独立预测因子。血清sLOX-1水平与AHI及高敏C反应蛋白水平显著相关。
结论
血清sLOX-1水平与OSA的存在及严重程度独立相关。这些发现表明，sLOX-1可能作为监测OSA发生和发展的潜在生物标志物。
Zotero 插件